G<b>apping up:<br/><br/>In reaction to strong earnings/guidance: </b>HK +16% (light volume), RHT +6.4%, BBRY +5.8%, DRI +2.9%, AIR +2.7% (light volume), CNC +2.6% (ticking higher), LEN +1.7%, DLTH +0.8%. <br/><br/><b>M&A news: </b>QIHU +2.8% (enters into a definitive merger agreement to be acquired by a consortium of investors in an all-cash transaction valued at ~$9.3 bln, or $77.00/share), . <br/><br/><b>Metals/mining stocks trading higher</b>: HMY +11.8%, SBGL +5.9%, AU +2.3%, ABX +2.3%, BHP +2% (also higher despite Moody's placing ratings of BHP Billiton on review for downgrade), MT +1.9% (also higher despite downgraded to Sector Perform at RBC Capital Mkts), RIO +1.7%, GDX +1.2%, SLV +0.9%, GLD +0.7%<br/>Other news: GPT +16.2% (Gramercy Property Trust and Chambers Street Properties close merger, complete private placement of $150 mln in senior unsecured notes, enter into new credit facility; initiated with a Buy at DA Davidson), GALE +4.1% (light volume, Galena Biopharma agress to sell Zuplenz to Midatech Pharma (MTP) for an upfront payment of $3.75 mln), BTU +6.8% (issues update, discloses potential plan to raise $150 mln in debt financing as well as a new $250 mln credit facility), JRJC +4.6% (announced that it has received ~$24.0 million from its investment in the Langfang real estate project, including fully recovered principal of ~$21.7 million.), TK +3.2% (following ~60% decline yesterday), NSPH +3.1% (prices $10 mln public offering of common stock at $0.47/share), CDXS +2.9% (ticking higher, announces multi-year contract extension to supply MSD with enzyme used in manufacture of Sitagliptin), RMBS +2.7% (to collaborate with Microsoft researchers in the exploration of future memory requirements for quantum computing), GMLP +2.5% (following ~30%+ decline yesterday), PTLA +1% (ticking higher, announces completion of BLA submission to FDA for Andexanet Alfa). <br/><br/><b>Analyst comments: </b>ROSG +4.8% (initiated with a Spec. Buy at Cantor Fitzgerald -- Thyroid may reveal ROSG to be your CUP of Tea), PLUG +3.2% (initiated with a Outperform at FBR Capital), SUNE +2.4% (initiated with a Outperform at FBR Capital; tgt $10.50), DERM +1.7% (upgraded to Buy from Neutral at Citigroup), FIT +1.4% (initiated with a Buy at Mizuho), DD +0.9% (upgraded to Buy at BofA/Merrill), CRM +0.7% (upgraded to Outperform from Neutral at Wedbush), EXAS +0.7% (initiated with a Buy at BTIG Research)<br/><br/><b>Gapping down:<br/><br/>In reaction to disappointing earnings/guidance: </b>DYSL -27% (thinly traded), KMX -8.8%, KNX -7.4% ( lowers Q4 EPS guidance below consensus, also downgraded to Neutral from Buy at Citigroup), AKS -2% (provides Q4 EPS guidance including charges; sees Q4 shipments of 1.6 mln tons, down 14% QoQ)<br/><br/><b>M&A related:</b> WFC -0.3% (Wells Fargo to sell its crop insurance business to Zurich Insurance). <br/><br/><b>Select telecom names showing early weakness</b>: TSU -5.3%, VIV -3.6%, TEF -2.9%, TMUS -1.3%. <br/><br/><b>Other news:</b> OSIR -12.8% (independent registered public accounting firm BDO USA resigns), QURE -8.6% (appoints Dan Soland as new CEO), ICPT -6.6% (FDA extends PDUFA date for Obeticholic acid for the treatment of PBC to May 29, 2016), VTAE -6.3% (announces top-line clinical efficacy results from the remaining monotherapy arm of Boehringer Ingelheim's Phase 2 trial of BI187004 in type 2 diabetes), VNR -5.7% (lowers monthly distribution to $0.03/unit from $0.1175/unit), ARIA -3.6% (confirms the appointment of Paris Panayiotopoulos as President and Chief Executive Officer, effective Jan. 1 2016), SWFT -3.3% (following KNX guidance), SCTY -2.9% (Jim Chanos reiterating cautious stance on SCTY- CNBC), YNDX -2.4% (Russia names weaker after Ukraine defaulted on $3 bln bond to Russia), VRX -2.1% (still checking), LVS -2% (CEO Adelson says the Macau market is beginning to bottom out - Reuters ), ALIM -2% (discloses it promoted Richard Eiswirth to the position of President and Chief Financial Officer), NE -1.8% (still checking), UN -1.6% (still checking), RIG -1.5% (Statoil ASA decides to cancel the contract with Transocean for the drillship Discoverer Americas; announced that the SIX Swiss Exchange approved its application to delist its shares), FDX -1.4% (pulling back following yesterday's earnings related strength), AN -1.3% (KMX sympathy), MS -1.2% (WSJ reports that Morgan Stanley is planning to trim up to 5% of its stock-trading employees early next year), IRMD -1.1% (announces a proposed secondary offering of common stock, by CEO Roger Susi; size not disclosed), AZN -1.1% (updates on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage therapy in patients with NSCLC), INTC -0.9% (still checking), JBHT -0.8% (following KNX guidance), YHOO -0.7% (NYPost reports that some of Yahoo's (YHOO) activist shareholders are mulling a proxy battle), MRK -0.4% (Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir; anticipates a European Commission decision in mid-2016), KR -0.3% (Kroger completes tender offer for shares of Roundy's; initiated with a Outperform at Wells Fargo). <br/><br/><b>Analyst comments:</b> FOSL -7.4% (downgraded to Sell from Neutral at Goldman), GLOP -2.3% (downgraded to Underweight from Neutral at JPMorgan), AIXG -1.2% (downgraded to Equal-Weight at Morgan Stanley), BA -1.1% (downgraded to Market Perform from Outperform at Wells Fargo), SGYP -0.7% (downgraded to Neutral from Buy at Citigroup), TXN -0.3% (downgraded to Mkt Perform from Outperform at Bernstein).<br/><br/>Allikas: Briefing.com